Metastatic Prostrate Cancer Predictive Test
Get the technology record
Summary
Prostate cancer is the second most common cancer, and the second leading cause of cancer death for men. This technology is aimed at patients who have already received a prostate cancer diagnosis. It can be used to identify which patients will develop metastasis so that treatment can be administered in time.
Potential Use
The metastatic prostate cancer prognostic test is expected to determine the probability of metastasis upon the initial diagnosis of cancer.
Development Status
TRL 5: Laboratory-scale test developed and validated through biopsies in patients in Chile, Unites States and Canada. Retrospective samples were included in the validation process, and prospective validations are currently underway.
Advantages
Alternatives currently available on the market (OncotypeDX, Prolaris and Decipher) do not provide a metastasis prognosis.
Improves patient’s life expectancy by reducing hospitalization costs otherwise incurred if not for the early prognosis of metastasis while also allowing for the administration of specific metastasis therapies in the early stages of the disease (upon initial diagnosis with a biopsy).
Intellectual Property
Patent request PCT/CL2017/050095, priority date December 29, 2017.
Opportunity
Looking for companies or institutions interested in financing the next stages of research.
Research Team
- Viviana Montecinos, PhD
- Javier Cerda, PhD